0000000000461661

AUTHOR

Costantina Prota

showing 4 related works from this author

Independent Impact of RV Involvement on In-Hospital Outcome of Patients With Takotsubo Syndrome

2016

Takotsubo syndrome (TTS) is an acute clinical condition characterized by transient left ventricular dysfunction and reversible heart failure, the pathogenetic mechanism of which remains unclear. Although left ventricular apical ballooning is the most frequent morphological pattern, other variant forms have been described (1). In addition, right ventricular involvement (RVi), characterized by the presence of right ventricular (RV) apical dysfunction (biventricular ballooning), has been documented using echocardiography or cardiac magnetic resonance imaging. However, the prevalence, clinical profile, and in-hospital course of TTS patients with RVi are still not well defined. To date, although…

Malemedicine.medical_specialtyCoronary Artery SpasmShock Cardiogenic030204 cardiovascular system & hematologyTakotsubo Cardiomyopathy Cardiogenic Shock Coronary Artery SpasmVentricular Function Left03 medical and health sciences0302 clinical medicineText miningPredictive Value of TestsRisk FactorsTakotsubo CardiomyopathyInternal medicineNuclear Medicine and ImagingmedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineHospital MortalityProspective StudiesAgedAged 80 and overCardiogenic ShockTakotsubo syndromeApical ballooningMechanism (biology)business.industryTakotsubo SyndromeRadiology Nuclear Medicine and Imaging; Cardiology and Cardiovascular MedicineMiddle Agedmedicine.diseasePrognosisHospitalizationHospital outcomesEchocardiographyHeart failureCardiologyVentricular Function RightFemalebusinessRadiologyCardiology and Cardiovascular Medicine
researchProduct

Long-term outcome in patients with Takotsubo syndrome presenting with severely reduced left ventricular ejection fraction

2019

Aim: To evaluate the long-term outcome of patients with Takotsubo syndrome (TTS) and severely reduced left ventricular ejection fraction (LVEF ≤ 35%) at presentation. Methods and results: The study population included 326 patients (mean age 69.5 ± 10.7 years, 28 male) with TTS enrolled in the Takotsubo Italian Network, divided into two groups according to LVEF (≤ 35%, n = 131; > 35%, n = 195), as assessed by transthoracic echocardiography at hospital admission. In-hospital events were recorded in both groups. At long-term follow-up (median 26.5 months, interquartile range 18–33), composite major adverse cardiac events (MACE: cardiac death, acute myocardial infarction, heart failure, and …

medicine.medical_specialtyLeft ventricular ejection fractionCardiomyopathyHeart failure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicinecardiovascular diseasesMyocardial infarctionCardiogenic shock; Cardiomyopathy; Heart failure; Left ventricular ejection fraction; Takotsubo syndromeCardiogenic shockEjection fractionbusiness.industryCardiogenic shockHazard ratiomedicine.diseaseConfidence intervalHeart failureCardiologybusinessTakotsubo syndromeCardiology and Cardiovascular MedicineCardiogenic shock; Cardiomyopathy; Heart failure; Left ventricular ejection fraction; Takotsubo syndrome; Cardiology and Cardiovascular MedicineMace
researchProduct

5037Drug treatment with beta-blockers and long-term outcome in patients with takotsubo syndrome: results from the takotsubo Italian network

2019

Abstract Background Although generally considered a benign disease, Takotsubo syndrome (TTS) has recently been associated to a substantially comparable long-term outcome than acute coronary syndrome (ACS). The use of beta-blockers (BB) has been advocated in these patients for secondary prevention after the index event, considering the presumed role of catecholamine in TTS pathophysiology. However, the effect of BB on long-term outcome remains controversial due to the paucity of data and the lack of evidence from randomized studies. Purpose To investigate the impact of BB therapy on long-term outcome in patients with TTS. Methods The study included all TTS patients enrolled in the Takotsubo …

medicine.medical_specialtyTakotsubo syndromebusiness.industrymedicine.diseaseTerm (time)PharmacotherapyHeart failureInternal medicinemedicineCardiologyIn patientCardiology and Cardiovascular MedicineBeta (finance)businessEuropean Heart Journal
researchProduct

Risk Stratification Using the CHA(2)DS(2)-VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

2017

Background The CHA 2 DS 2 ‐VASc score predicts stroke in patients with atrial fibrillation and has been reported to have a prognostic role even in acute coronary syndrome patients. The Takotsubo syndrome is a condition that mimics acute coronary syndrome and may present several complications including stroke. We sought to assess the ability of CHA 2 DS 2 ‐VASc score to predict adverse events in Takotsubo syndrome patients. Methods and Results Overall, 371 Takotsubo syndrome patients were enrolled in a prospective registry. Patients were divided into 3 groups according to the CHA 2 DS 2 ‐VASc score: Group A (≤1), B (2–3), and C (≥4). The median CHA 2 DS 2 ‐VASc score was 3 (interquartile ra…

MalePediatricsArrhythmias030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk FactorsInterquartile rangeOdds RatioCoronary Heart DiseaseProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionDSStrokeTakotsuboOriginal ResearchIncidenceMortality rateanticoagulant cardiovascular events CHA2DS2-VASc score stroke Takotsubo Takotsubo cardiomyopathy. Takotsubo syndromeAtrial fibrillationMiddle AgedPrognosisAnticoagulant; Cardiovascular events; CHA2DS2-VASc score; Stroke; Takotsubo; Takotsubo cardiomyopathy; Takotsubo syndrome; Cardiology and Cardiovascular MedicineStrokeItalyCardiologyFemaleCHA2DS2‐VASc scoreTakotsubo syndromeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeCHA2DS2-VASc scoreCardiomyopathy2Cardiovascular eventRisk Assessment-VASc scorecardiovascular events03 medical and health sciencesInternal medicinemedicineHumansAgedbusiness.industryAnticoagulantAnticoagulantsThrombosisOdds ratiomedicine.diseaseCHA2DS2–VASc scoreCHACerebrovascular Disease/StrokeTakotsubo cardiomyopathybusinessFollow-Up Studies
researchProduct